Sarah M. Russell

Sarah M. Russell

Auto-generated profile, based on publicly available information

Sarah M. Russell

Peter MacCallum Cancer Centre

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 1995 in Immunity
Verified
Journal Article
Closed access
XCXiqing Cao
Xiqing Cao
ESElizabeth W. Shores
Elizabeth W. Shores
JHJane Hu-Li
Jane Hu-Li
MAMiriam R. Anver
Miriam R. Anver
BKBrian L. Kelsail
Brian L. Kelsail
WLWarren J. Leonard
Warren J. Leonard

23 March 2007 in Science
Verified
Journal Article
Closed access
PDF file
JCJohn T. Chang
John T. Chang
VPVikram R. Palanivel
Vikram R. Palanivel
IKIchiko Kinjyo
Ichiko Kinjyo
FSFelix Schambach
Felix Schambach
AIAndrew M. Intlekofer
Andrew M. Intlekofer
SRSteven L. Reiner
Steven L. Reiner
A hallmark of mammalian immunity is the heterogeneity of cell fate that exists among pathogen-experienced lymphocytes. We show that a dividing T lymphocyte initially responding to a microbe exhibits unequal partitioning of proteins that mediate signaling, cell fate specification, and asymmetric cell division. Asymmetric segregation of determinants appears to be coordinated by prolonged interaction between the T cell and its antigen-presenting cell before division. Additionally, the first two daughter T cells displayed phenotypic and functional indicators of being differentially fated toward effector and memory lineages. These results suggest a mechanism by which a single lymphocyte can apportion diverse cell fates necessary for adaptive immunity.

1 May 1994 in Nature
Verified
Journal Article
Closed access
PDF file
YNYoshlaki Nakamura
Yoshlaki Nakamura
SRSarah M. Russell
Sarah M. Russell
SMSarah A. Mess
Sarah A. Mess
MFMichael Friedmann
Michael Friedmann
MEMichael Erdos
Michael Erdos
WLWarren J. Leonard
Warren J. Leonard

19 May 2003 in BioEssays
Verified
Journal Article
Closed access
PDF file
PHPatrick O. Humbert
Patrick O. Humbert
SRSarah Russell
Sarah Russell
HRHelena Richardson
Helena Richardson

1 June 2005 in Immunity
Verified
Journal Article
Closed access
MLMandy J. Ludford-Menting
Mandy J. Ludford-Menting
JOJane Oliaro
Jane Oliaro
FSFaruk Sacirbegovic
Faruk Sacirbegovic
ECEric T.-Y. Cheah
Eric T.-Y. Cheah
NPNatalie Pedersen
Natalie Pedersen
SRSarah M. Russell
Sarah M. Russell

1 December 2011 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
FWFlorian Wiede
Florian Wiede
BSBenjamin J. Shields
Benjamin J. Shields
SCSock Hui Chew
Sock Hui Chew
KKKonstantinos Kyparissoudis
Konstantinos Kyparissoudis
CVCatherine van Vliet
Catherine van Vliet
TTTony Tiganis
Tony Tiganis
Many autoimmune diseases exhibit familial aggregation, indicating that they have genetic determinants. Single nucleotide polymorphisms in PTPN2, which encodes T cell protein tyrosine phosphatase (TCPTP), have been linked with the development of several autoimmune diseases, including type 1 diabetes and Crohn’s disease. In this study, we have identified TCPTP as a key negative regulator of TCR signaling, which might explain the association of PTPN2 SNPs with autoimmune disease. We found that TCPTP dephosphorylates and inactivates Src family kinases to regulate T cell responses. Using T cell–specific TCPTP-deficient mice, we established that TCPTP attenuates T cell activation and proliferation in vitro and blunts antigen-induced responses in vivo. TCPTP deficiency lowered the in vivo threshold for TCR-dependent CD8+ T cell proliferation. Consistent with this, T cell–specific TCPTP-deficient mice developed widespread inflammation and autoimmunity that was transferable to wild-type recipient mice by CD8+ T cells alone. This autoimmunity was associated with increased serum levels of proinflammatory cytokines and anti-nuclear antibodies, T cell infiltrates in non-lymphoid tissues, and liver disease. These data indicate that TCPTP is a critical negative regulator of TCR signaling that sets the threshold for TCR-induced naive T cell responses to prevent autoimmune and inflammatory disorders arising.